Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HMPL-689 in Relapsed/Refractory Marginal Zone or Follicular Lymphoma
CTR20210264Phase 2Completed
- Sponsor
- HUTCHMED
- Start
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of amdizatinib in marginal zone B-cell lymphoma (MZL), follicular lymphoma (FL), sponsored by HUTCHMED. Started Feb 2021; status: completed.
02
Drugs
amdizatinib
03
Conditions
marginal zone B-cell lymphoma (MZL)follicular lymphoma (FL)
Beyond the preview
Go deeper on CTR20210264.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210264.